Human Genome Sciences: Innovative Partnering for Innovative Technology
Executive Summary
Even with the funds from its $125 million SmithKline collaboration (which, at the time of its signing, was an unprecedented investment in a biotech licensing), HGS needs plenty more collaborations if it is going to outlive the century. In its joint venture deals with Genetic Therapy Inc. and Isis, HGS is focusing on a strategy of finding third-party licensees, not letting these biotechs create proprietary products themselves.